LXR as a novel antithrombotic target

Blood

Volumn 117, Issue 21, 2011, Pages 5751-5761

  Spyridon, Michael ^a   Moraes, Leonardo A ^a   Jones, Chris I ^a   Sage, Tanya ^a   Sasikumar, Parvathy ^a   Bucci, Giovanna ^a   Gibbins, Jonathan M ^a,b  

^a UNIVERSITY OF READING   (United Kingdom)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; COLLAGEN RECEPTOR; LIVER X RECEPTOR BETA; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CALCIUM MOBILIZATION; CONTROLLED STUDY; HEART INFARCTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STROKE; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOSIS; THROMBUS;

EID: 79957620045     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-306142     Document Type: Article

References (53)

1. Chawla A, Repa JJ, Evans RM, et al. Nuclear receptors and lipid physiology: opening the X-files. Science. 2001;294(5548):1866-1870. (Pubitemid 33101573)
2. Lehmann JM, Kliewer SA, Moore LB, et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem. 1997;272(6):3137-3140. (Pubitemid 27066798)
3. Peet DJ, Turley SD, Ma W, et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell. 1998;93(5):693-704. (Pubitemid 28257577)
4. Repa JJ, Turley SD, Lobaccaro JA, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science. 2000;289(5484):1446-1447.
5. Singaraja RR, Bocher V, James ER, et al. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J Biol Chem. 2001;276(36):33969-33979.
6. Repa JJ, Berge KE, Pomajzl C, et al. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem. 2002;277(21):18793-18800. (Pubitemid 34952438)
7. Joseph SB, Castrillo A, Laffitte BA, et al. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med. 2003;9(2):213-219. (Pubitemid 36227724)
8. Fowler AJ, Sheu MY, Schmuth M, et al. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J Invest Dermatol. 2003;120(2):246-255. (Pubitemid 36513075)
9. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A. 2002;99(11):76049.
10. Tangirala RK, Bischoff ED, Joseph SB, et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci U S A. 2002;99(18):11896-11901. (Pubitemid 34994495)
11. Furman MI, Krueger LA, Linden MD, et al. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol. 2004;43(12):2319-2325. (Pubitemid 38757605)
12. Theilmeier G, Michiels C, Spaepen E, et al. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood. 2002;99(12):4486-4493. (Pubitemid 34627218)
13. Frenette PS, Johnson RC, Hynes RO, et al. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci U S A. 1995;92(16):7450-7454.
14. Lindemann S, Tolley ND, Dixon DA. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol. 2001;154(3):485-490. (Pubitemid 34286155)
15. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov. 2010;9(2):154-169.
16. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol. 2010;55(14):1487-1489.
17. Ali FY, Armstrong PC, Dhanji AR, et al. Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol. 2009;29(5):706-701.
18. Sadowitz B, Maier KG, Gahtan V. Basic science review. Statin therapy: I. The pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg. 2010;44(4):241-245.
19. Schroepfer GJ Jr. Oxysterols: modulators of cholesterol metabolism and other processes. Physiol Rev. 2000;80(1):361-365.
20. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996;84(2):289-297. (Pubitemid 26040846)
21. Gibbins JM, Okuma M, Farndale R, et al. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. FEBS Lett. 1997;413(2):255-259. (Pubitemid 27353279)
22. Tsuji M, Ezumi Y, Arai M, Takayama H. A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem. 1997;272(38):23528-23531. (Pubitemid 27410920)
23. Suzuki-Inoue K, Tulasne D, Shen Y, et al. Association of Fyn and Lyn with the proline-rich domain of glycoprotein VI regulates intracellular signaling. J Biol Chem. 2002;277(24):21561-21566. (Pubitemid 34952302)
24. Poole A, Gibbins JM, Turner MJ, et al. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J. 1997;16(9):2333-2341. (Pubitemid 27258634)
25. Gibbins JM, Briddon S, Shutes A, et al. The p85 subunit of phosphatidylinositol 3-kinase associates with the Fc receptor gamma-chain and linker for activitor of T cells (LAT) in platelets stimulated by collagen and convulxin. J Biol Chem. 1998;273(51):34437-34443. (Pubitemid 29008923)
26. Gross BS, Lee JR, Clements JL, et al. Tyrosine phosphorylation of SLP-76 is downstream of Syk following stimulation of the collagen receptor in platelets. J Biol Chem. 1999;274(9):5963-5971. (Pubitemid 29109256)
27. Oda A, Ikeda Y, Ochs HD. Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking. Blood. 2000;95(5):1663-1670. (Pubitemid 30120827)
28. Daniel JL, Dangelmaier C, Jin J, et al. Molecular basis for ADP-induced platelet activation: evidence for three distinct ADP receptors on human platelets. J Biol Chem. 1998;273(4):2024-2029. (Pubitemid 28069248)
29. Hirata M, Hayashi Y, Ushikubi F, et al. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature. 1991;349(6310):617-620. (Pubitemid 21912117)
30. Vu TK, Hung DT, Wheaton VI, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64(6):1057-1068. (Pubitemid 121001193)
31. Levin N, Bischoff ED, Daige CL, et al. Macrophage liver X receptor is required for anti-atherogenic activity of LXR agonists. Arterioscler Thromb Vasc Biol. 2005;25(1):135-142. (Pubitemid 40054266)
32. Moraes LA, Swales KE, Wray JA, et al. Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood. 2007;109(9):3741-3744. (Pubitemid 46641723)
33. Akbiyik F, Ray DM, Gettings KF, et al. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood. 2004;104(5):1361-1368. (Pubitemid 39166512)
34. Ali FY, Davidson SJ, Moraes LA, et al. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. FASEB J. 2006;20(2):326-328. (Pubitemid 46671159)
35. Moraes LA, Spyridon M, Kaiser WJ, et al. Nongenomic effects of PPARgamma ligands: inhibition of GPVI-stimulated platelet activation. J Thromb Haemost. 2010;(3)8:577-587.
36. Patil S, Gross PL, Stapleton M, et al. Platelet PE-CAM-1 inhibits thrombus formation in vivo. Blood. 2006;107(2):535-541. (Pubitemid 43076376)
37. Zhao C, Dahlman-Wright K. Liver X receptor in cholesterol metabolism. J Endocrinol. 2010;204(3):233-240.
38. Laffitte BA, Repa JJ, Joseph SB, et al. LXRs control lipid-inducible expression of the apoliprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci U S A. 2001;16(5):507-512. (Pubitemid 32105072)
39. Tucker KL, Sage T, Stevens JM, et al. A dual role for integrin linked kinase in platelets: regulating integrin function and alpha-granule secretion. Blood. 2008;112(12):4523-4531.
40. Yue L, Ye F, Gui C, et al. Ligand-binding regulation of LXR/RXR and LXR/PPAR heterodimerizations: SPR technology-based kinetic analysis correlated with molecular dynamics simulation. Protein Sci. 2005;14(3):812-822. (Pubitemid 40283920)
41. Bradley MN, Hong C, Chen M, et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Clin Invest. 2007;117(8):2337-2346. (Pubitemid 47219578)
42. Collins JL, Fivush AM, Watson MA, et al. Identification of a non-steroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J Med Chem. 2002;45(10):1963-1966. (Pubitemid 34477709)
43. Gratacap MP, Martin V, Valéra MC, et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversely affect platelet activation in vitro and in vivo. Blood. 2009;114(9):1884-1892.
44. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model. J Thromb Haemost. 2009;7(4):658-664.
45. Morello F, Saglio E, Noghero A, et al. LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms. Atherosclerosis. 2009;207(1):38-44.
46. Nofer J-R, Brodde MF, Kehrel BE. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin Exp Pharmacol Physiol. 2010;37(7):726-735.
47. Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: evidence for GPIIbIIIa-dependent mechanisms and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin and GPIalpha. J Exp Med. 1998;187(3):329-339. (Pubitemid 28080062)
48. Clark EA, Shattil SJ, Ginsberg MH, et al. Regulation of the protein tyrosine kinase pp72syk by platelet agonists and the integrin alpha IIb beta. J Biol Chem. 1994;269(46):28859-28864.
49. Arias-Salgado EG, Lizano S, Sarkar S, et al. Src kinase activation by direct interaction with the integrin beta cytoplasmic domain. Proc Natl Acad Sci U S A. 2003;100(23):13298-13302. (Pubitemid 37444736)
50. Woodside DG, Obergfell A, Leng L, et al. Activation of Syk protein tyrosine kinase through interaction with integrin beta cytoplasmic domains. Curr Biol. 2001;11(22):1799-1804. (Pubitemid 33092170)
51. Wonerow P, Pearce AC, Vaux DJ, et al. A critical role for phospholipase Cgamma2 in alpha IIb beta3-mediated platelet spreading. J Biol Chem. 2003;278(39):37520-37529. (Pubitemid 37175273)
52. Alberti S, Schuster G, Parini P, et al. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J Clin Invest. 2001;107(5):565-573. (Pubitemid 32206188)
53. Quinet EM, Savio DA, Halpern AR, et al. Liver X receptor (LXR)-beta regulation in LXRbeta-deficient mice: implications for therapeutic targeting. Mol Pharmacol. 2006;70(4):1340-1349. (Pubitemid 44435986)